Entity

ALLOX

Biotechnology - Therapeutics and Diagnostics

ALLOX was born out of the realization that combining systematic mutagenesis, high-throughput phenotyping and biophysical modelling has the potential to revolutionise drug development but also transform biotechnology in general. The company is a spin-off from the Centre for Genomic Regulation in Barcelona, and is founded by the researchers Ben Lehner, Júlia Domingo, Pablo Baeza and André Faure. We are developing a proprietary platform technology to design new drugs targeting protein allosteric sites to treat cancer and potentially many other diseases. Funded by Asabys Partners, a venture capital firm, and CDTI Innovation, a public business entity.